{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:01:36Z","timestamp":1787839296801,"version":"build-2784847793"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014717","name":"National Natural Science Foundation of China National Outstanding Youth Science Fund Project","doi-asserted-by":"publisher","award":["82260665"],"award-info":[{"award-number":["82260665"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.thromres.2025.109451","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:10:28Z","timestamp":1757031028000},"page":"109451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Effectiveness of health-related quality of life assessment scales in patients with haemophilia after treatment: Systematic review"],"prefix":"10.1016","volume":"254","author":[{"given":"John Sieh","family":"Dumbuya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashir","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cizheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.thromres.2025.109451_bb0010","first-page":"581","article-title":"Effects of a pain self-management intervention combining written and video elements on health-related quality of life among people with different levels of education","volume":"8","author":"Stalker","year":"2015","journal-title":"J. Pain Res."},{"issue":"4","key":"10.1016\/j.thromres.2025.109451_bb0015","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109451_bb0020","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hae.14363","article-title":"The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia a without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Skinner","year":"2021","journal-title":"Haemophilia"},{"issue":"17","key":"10.1016\/j.thromres.2025.109451_bb0025","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","article-title":"Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project","volume":"129","author":"Manco-Johnson","year":"2017","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.thromres.2025.109451_bb0030","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia a with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2025.109451_bb0035","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia a or B with investigational siRNA therapeutic fitusiran-results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"J Thromb Haemost JTH."},{"key":"10.1016\/j.thromres.2025.109451_bb0040","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620950836","article-title":"Safety, immunogenicity, and hemostatic efficacy of Nonacog gamma in patients with severe or moderately severe hemophilia B: a continuation study","volume":"26","author":"Windyga","year":"2020","journal-title":"Clin. Appl. Thromb."},{"issue":"22","key":"10.1016\/j.thromres.2025.109451_bb0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12955-024-02267-6","article-title":"Exploring the relationship between condition severity and health-related quality of life in people with haemophilia a across Europe: a multivariable analysis of data from the CHESS II study","volume":"29","author":"Ferri Grazzi","year":"2024","journal-title":"Health Qual. Life Outcomes"},{"issue":"8","key":"10.1016\/j.thromres.2025.109451_bb0050","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1055\/s-0035-1552564","article-title":"Assessing activities, participation, and quality of life in hemophilia: relevance, current limitations, and possible options","volume":"41","author":"David","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0055","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13023-022-02343-4","article-title":"Healthcare access, satisfaction, and health-related quality of life among children and adults with rare diseases","volume":"17","author":"Bogart","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"15","key":"10.1016\/j.thromres.2025.109451_bb0060","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2147\/PPA.S326434","article-title":"Quality of life, perception of disease and coping strategies in patients with hemophilia in Spain and El Salvador: a comparative study","volume":"21","author":"Cuesta-Barriuso","year":"2021","journal-title":"Patient Prefer. Adherence"},{"issue":"4","key":"10.1016\/j.thromres.2025.109451_bb0065","first-page":"e161","article-title":"Depressive symptoms and adherence to prophylaxis in patients with haemophilia from Croatia and Slovenia","volume":"26","author":"Bago","year":"2020","journal-title":"Haemoph Off J World Fed Hemoph."},{"issue":"6","key":"10.1016\/j.thromres.2025.109451_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12576","article-title":"Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety","volume":"5","author":"Mahlangu","year":"2021","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0075","first-page":"11","article-title":"Do therapeutic exercises improve Kinesophobia and health-related quality of life in adult hemophilia patients? A randomized controlled trial","volume":"3","author":"Deniz","year":"2020","journal-title":"Int J Disabil Sports Health Sci."},{"issue":"3","key":"10.1016\/j.thromres.2025.109451_bb0080","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach","volume":"13","author":"Aromataris","year":"2015","journal-title":"Int. J. Evid. Based Healthc."},{"issue":"12","key":"10.1016\/j.thromres.2025.109451_bb0085","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/CORR.0000000000002264","article-title":"No benefit to platelet-rich plasma over placebo injections in terms of pain or function in patients with hemophilic knee arthritis: a randomized trial","volume":"480","author":"Duan","year":"2022","journal-title":"Clin. Orthop."},{"issue":"26","key":"10.1016\/j.thromres.2025.109451_bb0090","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2025.109451_bb0095","doi-asserted-by":"crossref","DOI":"10.1093\/tropej\/fmac039","article-title":"Twice weekly vs. thrice weekly low-dose prophylactic factor VIII therapy in children with hemophilia a: an open label randomized trial","volume":"68","author":"Gomber","year":"2022","journal-title":"J. Trop. Pediatr."},{"issue":"Supplement 1","key":"10.1016\/j.thromres.2025.109451_bb0100","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1182\/blood-2022-167169","article-title":"Fitusiran prophylaxis improves health-related quality of life in people with hemophilia a or B, with or without inhibitors: results of ATLAS-PPX study","volume":"140","author":"Kenet","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2025.109451_bb0105","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia a","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2025.109451_bb0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/hae.14977","article-title":"Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: results from the phase III HOPE-B trial 2 years after gene therapy","volume":"30","author":"Itzler","year":"2024","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.thromres.2025.109451_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12670","article-title":"Prophylactic emicizumab for hemophilia a in the Asia-Pacific region: a randomized study (HAVEN 5)","volume":"6","author":"Yang","year":"2022","journal-title":"Res Pract Thromb Haemost."},{"key":"10.1016\/j.thromres.2025.109451_bb0120","doi-asserted-by":"crossref","DOI":"10.1177\/1076029621989811","article-title":"Phase 4 safety and efficacy study of antihemophilic factor (recombinant) in previously treated Chinese patients with severe\/moderately severe hemophilia a","volume":"27","author":"Zhao","year":"2021","journal-title":"Clin. Appl. Thromb."},{"issue":"6","key":"10.1016\/j.thromres.2025.109451_bb0125","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/hae.14184","article-title":"Determining meaningful health-related quality-of-life improvement in persons with haemophilia a using the Haemophilia quality of life questionnaire for adults (Haem-A-QoL)","volume":"26","author":"von Mackensen","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia a with inhibitors: HAVEN 1 study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemoph Off J World Fed Hemoph."},{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/hae.13624","article-title":"Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP","volume":"25","author":"von Mackensen","year":"2019","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.thromres.2025.109451_bb0140","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/hae.12371","article-title":"Assessment of the impact of treatment on quality of life of patients with haemophilia a at different ages: insights from two clinical trials on turoctocog alfa","volume":"20","author":"Santagostino","year":"2014","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.thromres.2025.109451_bb0145","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hae.13119","article-title":"Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia a","volume":"23","author":"Mullins","year":"2017","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.thromres.2025.109451_bb0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/ejh.13420","article-title":"BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia a: interim results from the TAURUS study","volume":"105","author":"Santoro","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.thromres.2025.109451_bb0155","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2025.109451_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12552","article-title":"Significant reduction in hemarthrosis in boys with severe hemophilia a: the China hemophilia individualized low-dose secondary prophylaxis study","volume":"5","author":"Wu","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2025.109451_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12837","article-title":"Safety and efficacy of long-term emicizumab prophylaxis in hemophilia a with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY)","volume":"6","author":"Jim\u00e9nez-Yuste","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/jmedsci.jmedsci_33_18","article-title":"Efficacy, safety, and synovial effects of intra-articular hyaluronic acid in treating recalcitrant hemophilic Arthropathy of knee joint","volume":"39","author":"Li","year":"2019","journal-title":"J. Med. Sci."},{"issue":"3","key":"10.1016\/j.thromres.2025.109451_bb0175","first-page":"379","article-title":"Effect of neurodynamics nerve flossing on femoral neuropathy in Haemophilic patients: a randomized controlled study","volume":"21","author":"Hamed","year":"2021","journal-title":"J. Musculoskelet. Neuronal Interact."},{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0180","doi-asserted-by":"crossref","first-page":"13399","DOI":"10.1038\/s41598-019-49827-1","article-title":"Effectiveness of hypnosis for pain management and promotion of health-related quality-of-life among people with haemophilia: a randomised controlled pilot trial","volume":"9","author":"Paredes","year":"2019","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.thromres.2025.109451_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12613","article-title":"Project GYM: a randomized feasibility study investigating effect on motivation of personal trainer-led exercise in young men with hemophilia","volume":"5","author":"McLaughlin","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109451_bb0190","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5152\/TurkArchPediatr.2023.22226","article-title":"The effects of exercise training on physical activity level, daily living activities, and participation in children with hemophilia","volume":"58","author":"Atay","year":"2023","journal-title":"Turk Arch Pediatr."},{"issue":"9","key":"10.1016\/j.thromres.2025.109451_bb0195","first-page":"81","article-title":"Effect of pulsed electromagnetic fields on clinical signs and quality of life in patients with hemophilic Arthropathy of the knee joint: a randomized controlled trial","volume":"23","author":"Khami","year":"2020","journal-title":"Adv. Biomed. Res."},{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0200","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/hae.14444","article-title":"Effects of a supervised therapeutic exercise program on musculoskeletal health and gait in patients with haemophilia: a pilot study","volume":"28","author":"Deniz","year":"2022","journal-title":"Haemoph Off J World Fed Hemoph."},{"issue":"4","key":"10.1016\/j.thromres.2025.109451_bb0205","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/hae.12617","article-title":"Impact of severe haemophilia a on patients\u2019 health status: results from the guardian\u2122 1 clinical trial of turoctocog alfa (NovoEight\u00ae)","volume":"21","author":"Ozelo","year":"2015","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2025.109451_bb0210","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s12325-020-01374-2","article-title":"Comparing physician and patient perspectives on prophylactic treatment with BAY 94-9027 for severe Haemophilia a: a post hoc analysis","volume":"37","author":"Lalezari","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.thromres.2025.109451_bb0215","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2147\/PPA.S196103","article-title":"Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII","volume":"13","author":"Kearney","year":"2019","journal-title":"Patient Prefer. Adherence"},{"issue":"11","key":"10.1016\/j.thromres.2025.109451_bb0220","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia a: results of the joint outcome continuation study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.thromres.2025.109451_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102180","article-title":"Prophylaxis with a recombinant factor VIII fc in hemophilia a: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults","volume":"7","author":"Konkle","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109451_bb0230","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/MBC.0000000000000584","volume":"28","author":"Lentz","year":"2017","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0235","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1538-7836.2009.03650.x","article-title":"Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia a: results from a 13-month crossover study","volume":"8","author":"Collins","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109451_bb0240","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241257917","article-title":"Long-term efmoroctocog alfa prophylaxis improves perceived pain, mental, and physical health in patients with hemophilia a: post hoc analysis of phase III trials using patient-reported outcomes","volume":"15","author":"Raheja","year":"2024","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.thromres.2025.109451_bb0245","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jth.14959","article-title":"Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2","volume":"18","author":"Giangrande","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2025.109451_bb0250","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1111\/hae.14052","article-title":"Long-term safety and efficacy results from the phase 3b, open-label, multicentre continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia a","volume":"26","author":"Chowdary","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109451_bb0255","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221079482","article-title":"Improvement in pain-related quality of life in patients with hemophilia a treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study","volume":"13","author":"Pasi","year":"2022","journal-title":"Ther. Adv. Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109451_bb0260","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ejh.13900","article-title":"Effectiveness of progressive moderate-vigorous intensity elastic resistance training on quality of life and perceived functional abilities in people with hemophilia: secondary analysis of a randomized controlled trial","volume":"110","author":"Cruz-Montecinos","year":"2023","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2025.109451_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102163","article-title":"Long-term outcomes of prophylaxis with a recombinant factor VIII fc or recombinant factor IX fc in patients with hemophilia previously treated on demand","volume":"7","author":"\u00c1lvarez-Rom\u00e1n","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2025.109451_bb0270","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/hae.14735","article-title":"Effectiveness of therapeutic exercise and cognitive-behavioural therapy combined protocol on functionality, pain and joint health in people with haemophilia: secondary analysis of a controlled trial","volume":"29","author":"Moreno-Segura","year":"2023","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2025.109451_bb0275","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/hae.14183","article-title":"Health-related quality of life and caregiver burden of emicizumab in children with haemophilia a and factor VIII inhibitors\u2014results from the HAVEN 2 study","volume":"26","author":"Mancuso","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0280","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hae.14455","article-title":"rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires","volume":"28","author":"Astermark","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109451_bb0285","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231170701","article-title":"Recombinant factor IX fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes","volume":"14","author":"Astermark","year":"2023","journal-title":"Ther Adv Hematol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109451_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102476","article-title":"Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study","volume":"8","author":"Tran","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109451_bb0295","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/jth.15036","article-title":"Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia a: final results from pathfinder5","volume":"18 Suppl 1(Suppl 1)","author":"\u0160aulyt\u0117 Trakymien\u0117","year":"2020","journal-title":"J Thromb Haemost JTH."},{"key":"10.1016\/j.thromres.2025.109451_bb0300","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/JBM.S354526","article-title":"Comorbidities, health-related quality of life, health-care utilization in older persons with hemophilia\u2014hematology utilization group study part VII (HUGS VII)","volume":"13","author":"Curtis","year":"2022","journal-title":"J Blood Med."},{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0305","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12955-024-02324-0","article-title":"Assessing the effectiveness of measurement scales in evaluating the health-related quality of life in rare disease patients after treatment: a systematic review","volume":"22","author":"Dumbuya","year":"2024","journal-title":"Health Qual. Life Outcomes"},{"issue":"1","key":"10.1016\/j.thromres.2025.109451_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169880","article-title":"Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a quantitative study with patients","volume":"12","author":"van Os","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.thromres.2025.109451_bb0315","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/hae.12618","article-title":"Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia a","volume":"21","author":"Garc\u00eda-Das\u00ed","year":"2015","journal-title":"Haemoph Off J World Fed Hemoph."},{"issue":"6","key":"10.1016\/j.thromres.2025.109451_bb0320","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jval.2014.07.003","article-title":"Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: observations from the dosing observational study in hemophilia (DOSE)","volume":"17","author":"Recht","year":"2014","journal-title":"Value Health. J. Int. Soc. Pharmacoecon. Outcomes Res."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:38:44Z","timestamp":1762249124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825002014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":64,"alternative-id":["S0049384825002014"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109451","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of health-related quality of life assessment scales in patients with haemophilia after treatment: Systematic review","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109451"}}